Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.9901 USD -1.97% Intraday chart for Mainz Biomed N.V. -9.17% -14.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mainz Biomed N.V. Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic CI
Mainz Biomed Announces Distribution Partnership with Praxisdienst for Coloalert® CI
Mainz Biomed N.V. Establishes Strategic Partnership with Tomalab to Expand Availability of Coloalert in Italy CI
Certain Ordinary Shares of Mainz Biomed N.V. are subject to a Lock-Up Agreement Ending on 14-FEB-2024. CI
Mainz Biomed Launches New Laboratory in Germany MT
Mainz Biomed N.V. and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees CI
Mainz Biomed N.V. Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers CI
Cantor Fitzgerald Downgrades Mainz Biomed to Neutral From Overweight MT
HC Wainwright Adjusts Mainz Biomed's Price Target to $5 From $9, Keeps Buy Rating MT
Mainz Biomed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading MT
Top Midday Decliners MT
Mainz Biomed Targets $5 Million in Direct Offering with Institutional Investors MT
Mainz Biomed Nv Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence to Develop Next-Generation Colorectal Screening Test CI
Mainz Biomed N.V. Presents Results of Colofuture Study CI
Mainz Biomed Launches Colorectal Cancer Detection Test in Romania MT
Mainz Biomed, Bioclinica Introduce Colorectal Cancer Screening Test in Romania MT
Mainz Biomed N.V. Announces Live Launch of Coloalert® with Bioclinica in Romania CI
Mainz Biomed N.V.(NasdaqCM:MYNZ) dropped from S&P Global BMI Index CI
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Mainz Biomed's Colorectal Cancer Screening Trial Yields Positive Topline Results MT
Mainz Biomed Says Clinical Study Assessing Novel mRNA Biomarkers for Colorectal Cancer Test Showed 'Positive' Results MT
Mainz Biomed N.V. Announces Positive Topline Results from its ColoFuture Study CI
Mainz Biomed Signs Strategic Partnership with German Laboratory MT
Mainz Biomed Taps Arztliches Labor Dr. Buhlmann as Partner for ColoAlert in Germany MT
Chart Mainz Biomed N.V.
More charts
Mainz Biomed B.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9901 USD
Average target price
3 USD
Spread / Average Target
+203.00%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Mainz Biomed N.V. - Nasdaq
  4. News Mainz Biomed N.V.
  5. Health Care Stocks Mixed Ahead of Wednesday's Open